Related Experiment Video
Updated: Oct 30, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy
Mohamed M El-Kady1, Reham A Naggar2, Maha Guimei3
1Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo 11559, Egypt.
Abstract:
Diabetic kidney disease (DKD) is still one of the unresolved major complications of diabetes mellitus, which leads ultimately to end-stage renal disease in both type 1 and type 2 diabetes patients. Available drugs that suppress the renin-angiotensin system have partially minimized the disease impact. Yet, there is an unmet need for new therapeutic interventions to protect the kidneys of diabetic patients. In DN, glomerular sclerosis and tubulointerstitial fibrosis are mediated through several pathways, of which JAK/STAT is a key one. The current study explored the potential renoprotective effect of the JAK1/JAK2 inhibitor ruxolitinib (at doses of 0.44, 2.2, and 4.4 mg·kg-1) compared to that of enalapril at a dose of 10 mg·kg-1, in a rat model of streptozotocin-induced diabetes mellitus over 8 weeks. The effect of ruxolitinib was assessed by determining urinary albumin/creatinine ratio, serum level of cystatin, and levels of TGF-β1, NF-κB, and TNF-α in renal tissue homogenates by biochemical assays, the glomerular sclerosis and tubulointerstitial fibrosis scores by histological analysis, and fibronectin, TGF-β1, and Vimentin levels by immunohistochemical staining with the respective antibodies. Our results revealed a significant early favorable effect of a two-week ruxolitinib treatment on the renal function, supported by a decline in the proinflammatory biomarkers of DKD. This pre-clinical study suggests that the renoprotective effect of ruxolitinib in the long term should be investigated in animals, as this drug may prove to be a potential option for the treatment of diabetic kidney disease.
Insights
Ruxolitinib, a JAK inhibitor, shows early promise in protecting kidneys from diabetic kidney disease (DKD) in rats. Further long-term studies are needed to confirm its potential as a novel therapeutic option for DKD.
Area of Science:
- Nephrology
- Pharmacology
- Diabetology
Background:
- Diabetic kidney disease (DKD) is a major diabetes complication leading to end-stage renal disease.
- Current treatments targeting the renin-angiotensin system offer only partial protection.
- The JAK/STAT pathway is implicated in the pathogenesis of diabetic nephropathy (DN), highlighting a need for new therapeutic targets.
Purpose of the Study:
- To investigate the potential renoprotective effects of the JAK1/JAK2 inhibitor ruxolitinib in a rat model of DKD.
- To compare the efficacy of ruxolitinib with enalapril, a standard treatment, in mitigating DKD progression.
Main Methods:
- A rat model of streptozotocin-induced diabetes was used over 8 weeks.
- Ruxolitinib was administered at varying doses (0.44, 2.2, 4.4 mg·kg⁻¹), alongside enalapril (10 mg·kg⁻¹).
- Renal function was assessed via urinary albumin/creatinine ratio and serum cystatin; inflammation and fibrosis markers (TGF-β1, NF-κB, TNF-α) and histological changes were evaluated.
Main Results:
- Ruxolitinib demonstrated a significant early improvement in renal function within two weeks of treatment.
- A notable reduction in pro-inflammatory biomarkers associated with DKD was observed.
- Histological analysis indicated reduced glomerular sclerosis and tubulointerstitial fibrosis.
Conclusions:
- Ruxolitinib exhibits promising early renoprotective effects in a preclinical DKD model.
- The drug's ability to reduce inflammation and fibrosis suggests potential therapeutic value.
- Further long-term animal studies are warranted to explore ruxolitinib as a treatment for diabetic kidney disease.
